TIMBER!
$Allakos(ALLK.US$ Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary Endpoints![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Too bad
TrytosaveabitOP Jaguar8: Yup! Really SUX! Anyways Good morning my friend! GL today
Jaguar8 TrytosaveabitOP: Good morning!